HIV-1 Fusion Inhibitor Peptides Enfuvirtide and T-1249 Interact with Erythrocyte and Lymphocyte Membranes

Pedro M. Matos, Miguel A. R. B. Castanho, Nuno C. Santos · 2010

Read HIV-1 Fusion Inhibitor Peptides Enfuvirtide and T-1249 Interact with Erythrocyte and Lymphocyte Membranes by Pedro M. Matos, Miguel A. R. B. Castanho, Nuno C. Santos (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0009830.txt.

Description

Some HIV drugs work by blocking the virus from fusing with human cells. Pedro Matos and colleagues studied two such fusion inhibitor peptides, enfuvirtide and T-1249. Their study appeared in PLOS ONE in 2010.

The team watched how the peptides interact with cell membranes. They used membranes from erythrocytes, red blood cells, and lymphocytes, white blood cells of the immune system. How a drug peptide meets the membrane affects how well it can work. Membrane contact is the first step in blocking fusion. The details help chemists design stronger fusion blockers.

Catalog record

CREATORPedro M. Matos, Miguel A. R. B. Castanho, Nuno C. Santos
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0009830

Browse the full library · About the Tower of Babel